- Celyad Oncology CYAD provides an update on its Celyad 2.0 business strategy, which has been adopted and implemented over the last few months.
- The company has compiled a foundational and broad IP estate.
- In addition to IP partnering transactions, Celyad 2.0 will prioritize discovery research in areas including:
- Multiplexing approach of the short hairpin RNA (shRNA) platform.
- Dual CAR development of a next-generation NKG2D-based CAR.
- Development of B7-H6-targeting immunotherapies for several cancers.
- Celyad has decided to discontinue the development of its remaining clinical program, CYAD-211 (the allogeneic shRNA-based, anti-BCMA CAR T candidate for relapsed or refractory multiple myeloma.
- No safety concerns led to this decision, and all patients previously treated with CYAD-211 will continue to receive their protocol-defined follow-up.
- In its Q3 earnings release, the company decided to discontinue the development of CYAD-101 following the previously announced clinical hold resolution.
- The company will provide updates on the potential proof-of-concept of the dual CAR and multiplexing research programs and business development in Q2 of 2023.
- Price Action: CYAD shares are down 34.72% at $0.6789 during the premarket session on the last check Wednesday.
- Photo Via Company
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.